ArticleThe EMBO journal1998
p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53.
Article in The EMBO journal, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 97 citations in OpenAlex.
- Article
- JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication.JHEP reports : innovation in hepatology · 2023Article
- Article
- Association of Nucleostemin Polymorphisms with Chronic Hepatitis B Virus Infection in Chinese Han Population.Genetic testing and molecular biomarkers · 2022Article
- SIRT2 Promotes HBV Transcription and Replication by Targeting Transcription Factor p53 to Increase the Activities of HBV Enhancers and Promoters.Frontiers in microbiology · 2022Article
- RFX1: a promising therapeutic arsenal against cancer.Cancer cell international · 2021Review
- Peptides to combat viral infectious diseases.Peptides · 2020Review
- Article
- Review
- Adenosine deaminase acting on RNA-1 (ADAR1) inhibits hepatitis B virus (HBV) replication by enhancing microRNA-122 processing.The Journal of biological chemistry · 2019Article
- Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection.Emerging microbes & infections · 2019Article
- Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma.World journal of hepatology · 2018Review
- MicroRNAs as Important Players in Host-hepatitis B Virus Interactions.Journal of clinical and translational hepatology · 2015Review
- p53 suppresses muscle differentiation at the myogenin step in response to genotoxic stress.Cell death and differentiation · 2015Article
- Complex interactions between microRNAs and hepatitis B/C viruses.World journal of gastroenterology · 2014Review
- Identification of two novel functional p53 responsive elements in the herpes simplex virus-1 genome.Virology · 2014Article
- MicroRNAs associated with HBV infection and HBV-related HCC.Theranostics · 2014Review
- Nucleotide changes related to hepatocellular carcinoma in the enhancer 1/x-promoter of hepatitis B virus subgenotype C2 in cirrhotic patients.Cancer science · 2010Article
- Transcriptional regulation by p53.Cold Spring Harbor perspectives in biology · 2010Review
- p53 responsive elements in human retrotransposons.Oncogene · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The transcription program of the hepatitis B virus (HBV) genome is regulated by an enhancer element that binds multiple ubiquitous and liver-enriched transcription activators. HBV transcription and replication are repressed in the presence of p53. Here we describe a novel molecular mechanism that is responsible for this repression. The p53 protein binds to a defined region within the HBV enhancer in a sequence-specific manner, and this, surprisingly, results in p53-dependent transcriptional repression in the context of the whole HBV enhancer. This unusual behavior of the HBV enhancer can be reconstituted by replacing its p53-binding region with the p53-binding domain of the mdm2 promoter. Remarkably, mutation of the EP element of the enhancer reversed the effect of p53 from repression to transcriptional stimulation. Furthermore, EP-dependent modulation of p53 activity can be demonstrated in the context of the mdm2 promoter, suggesting that EP is not only required but is also sufficient to convert p53 activity from positive to negative. Our results imply that the transcriptional effect of DNA-bound p53 can be dramatically modulated by the DNA context and by adjacent DNA-protein interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.